Allineane

Allineane is a synthetic cannabinoid compound that belongs to the aminoalkylindole class of designer drugs. It was first identified in 2012 and is structurally related to other synthetic cannabinoids like JWH-018 and JWH-073. The compound acts as a potent agonist at cannabinoid receptors CB1 and CB2, producing effects similar to those of natural cannabis but often with significantly greater intensity.

Chemically, Allineane features a naphthoylindole core structure with specific substitutions that enhance its binding affinity to cannabinoid receptors. Its molecular formula is C25H24N2O2, and it is typically encountered as a white crystalline powder. The compound is soluble in organic solvents but has limited solubility in water.

The substance gained attention in the research chemical market as manufacturers sought to create novel compounds that could circumvent existing drug laws. Allineane was marketed under various names and sold as "legal highs" or "herbal incense" products, often labeled as not intended for human consumption. However, its sale and possession have been restricted or banned in many jurisdictions due to safety concerns.

Pharmacological studies indicate that Allineane produces psychoactive effects including altered perception, euphoria, and relaxation, but it can also cause severe side effects such as anxiety, paranoia, rapid heart rate, and in some cases, more serious cardiovascular complications. The compound's potency and unpredictable effects make it particularly dangerous, especially when consumed in unknown quantities or combined with other substances.

Research on Allineane remains limited, with most available data coming from forensic toxicology reports and emergency room cases. The compound represents part of a broader category of synthetic cannabinoids that continue to pose challenges for regulatory agencies and healthcare providers due to their rapidly evolving chemical structures and unpredictable pharmacological profiles.